Circulation, Vol 71, 332-340, Copyright © 1985 by American Heart Association
BB Weksler, K Tack-Goldman, VA Subramanian and WA Gay Jr
The relationship between the antithrombotic and antiplatelet effects of
aspirin is complex, since aspirin influences other systems that protect
against thrombosis as well as inhibiting platelet function. We investigated
possible cumulative effects of low-dose aspirin on vascular production of
prostacyclin in patients with documented atherosclerotic cardiovascular
disease. Candidates for coronary artery vein graft bypass ingested 20 mg of
aspirin daily during the week before surgery, and platelet aggregation,
platelet formation of thromboxane A2 (TXA2), aortic and saphenous vein
production of prostacyclin (PGI2), and hemostatic status were measured at
the time of the bypass surgery. Low-dose aspirin markedly inhibited
platelet aggregation responses and reduced TXA2 generation by greater than
90%, effects similar to those observed with much higher doses of aspirin.
Both aortic and saphenous vein production of PGI2 were inhibited by 50%
compared with PGI2 produced by vascular tissues of control subjects who
received no aspirin preoperatively (51 +/- 10 pg 6-keto-PGF1 alpha/mg
aortic wet weight [mean +/- SEM] in aspirin-treated subjects vs 130 +/- 16
pg/mg in control subjects, and 71 +/- 8 pg/mg saphenous vein wet weight vs
131 +/- 17 pg/mg). Blood loss at surgery was not significantly increased by
preoperative low-dose aspirin as measured by chest tube drainage (754 +/-
229 ml in aspirin-treated subjects vs 645 +/- 271 ml in control subjects),
hematocrit nadir (31.2 +/- 1.9% vs 31.8 +/- 1.7%), or transfusions (2.2 +/-
1.3 units of red blood cells vs 2.2 +/- 1.7 units).(ABSTRACT TRUNCATED AT
250 WORDS)
ARTICLES
Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerosis
This article has been cited by other articles:
![]() |
B. F. McAdam, D. Byrne, J. D. Morrow, and J. A. Oates Contribution of Cyclooxygenase-2 to Elevated Biosynthesis of Thromboxane A2 and Prostacyclin in Cigarette Smokers Circulation, August 16, 2005; 112(7): 1024 - 1029. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Klein, P.R. Keith, H.-P. Dauben, H.D. Schulte, H. Beckmann, G. Mayer, O. Elert, and E. Gams Aprotinin counterbalances an increased risk of peri-operative haemorrhage in CABG patients pre-treated with Aspirin Eur. J. Cardiothorac. Surg., October 1, 1999; 14(4): 360 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Eisenberg and E. J. Topol Prehospital Administration of Aspirin in Patients With Unstable Angina and Acute Myocardial Infarction Arch Intern Med, July 22, 1996; 156(14): 1506 - 1510. [Abstract] [PDF] |
||||
![]() |
R. J. Shebuski Interruption of Thrombosis and Hemostasis by Anti-Platelet Agents Toxicol Pathol, January 1, 1993; 21(2): 180 - 189. [Abstract] [PDF] |
||||
![]() |
M. D. McDaniel, W. T. Huntsman, T. OC. Miett, and J. L. Cronenwett Effect of a Selective Thromboxane Synthase Inhibitor on Arterial Graft Patency and Platelet Deposition in Dogs Arch Surg, August 1, 1987; 122(8): 887 - 892. [Abstract] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1985 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |